Altius Minerals Corp (ATUSF) 7.0300 $ATUSF Altius

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Altius Minerals Corp (ATUSF) 7.0300 $ATUSF

Altius Minerals Corporation (TSX: ALS) Reports Annual Attributable Revenue of $33,085,000 and Adjusted EBITDA of $25,499,000; Declares Quarterly Dividend
Marketwired - Thu Jun 23, 8:25AM CDT
ST. JOHN'S, NEWFOUNDLAND AND LABRADOR--(Marketwired - Jun 23, 2016) - Altius Minerals Corporation ("Altius" or the "Corporation" (TSX:ALS) reports annual attributable revenue(1) of $33,085,000 or $0.83 per share and adjusted EBITDA(2) of $25,499,000 or $0.64 per share compared to attributable revenue of $28,808,000 or $0.90 per share and adjusted EBITDA of $22,881,000 or $0.71 per share for last year. The increases are largely attributable to growth in base metals royalty revenue as a result of the addition of the 777 Mine royalty to the Corporation's portfolio.
ALS.TO: 9.03 (-0.06)

Altius (TSX: ALS) Completes Chapada Copper Purchase Agreement and Closes Debt Financing
Marketwired - Wed May 04, 8:24AM CDT
ST. JOHN'S, NEWFOUNDLAND AND LABRADOR--(Marketwired - May 4, 2016) - Altius Minerals Corporation (TSX:ALS) ("Altius" is pleased to report that it has successfully closed the previously announced copper purchase agreement related to the Chapada copper-gold mine located in central Brazil. A final payment of US$52 million and 400,000 common share purchase warrants of Altius has been made to a subsidiary of Yamana Gold Inc. ("Yamana", which now completes the US$60 million transaction. Under the terms of the copper purchase agreement Altius is entitled to purchase 3.7% of the payable copper produced from the Chapada mine at 30% of the market price. This rate is subject to certain future potential adjustments as fully described in the Altius news release dated March 31, 2016.
ALS.TO: 9.03 (-0.06)

Altius Minerals Up 43.2% Since SmarTrend Uptrend Call (ATUSF)
Comtex SmarTrend(R) - Thu Apr 28, 1:24PM CDT
SmarTrend identified an Uptrend for Altius Minerals (NASDAQ:ATUSF) on February 4th, 2016 at $6.22. In approximately 3 months, Altius Minerals has returned 43.20% as of today's recent price of $8.90.

Uptrend Call Working As Altius Minerals Stock Rises 43.2% (ATUSF)
Comtex SmarTrend(R) - Thu Apr 21, 12:59AM CDT
SmarTrend identified an Uptrend for Altius Minerals (NASDAQ:ATUSF) on February 4th, 2016 at $6.22. In approximately 3 months, Altius Minerals has returned 43.20% as of today's recent price of $8.90.

Altius (TSX: ALS) Acquires Copper Payments Referenced to Yamana's Chapada Mine
Marketwired - Thu Mar 31, 5:26PM CDT
Altius Minerals Corporation (TSX: ALS) ("Altius" is pleased to report that it has entered into a metal purchase agreement with a subsidiary of Yamana Gold Inc. ("Yamana" to acquire future copper payments referenced to Yamana's Chapada copper-gold mine located in central Brazil.
ALS.TO: 9.03 (-0.06)

Altius Declares Quarterly Dividend of $0.03 per Share
Marketwired - Tue Mar 22, 3:30PM CDT
Altius Minerals Corporation ("Altius" (TSX: ALS) is pleased to announce that its board of directors has declared a cash dividend on its common shares of three cents per common share to all shareholders of record at the close of business on April 6, 2016. The dividend is expected to be paid on or about April 20, 2016.
ALS.TO: 9.03 (-0.06)

Altius Minerals Up 37.4% Since SmarTrend Uptrend Call (ATUSF)
Comtex SmarTrend(R) - Tue Mar 22, 12:09AM CDT
SmarTrend identified an Uptrend for Altius Minerals (NASDAQ:ATUSF) on February 4th, 2016 at $6.22. In approximately 2 months, Altius Minerals has returned 37.41% as of today's recent price of $8.54.

Altius Minerals Corporation Reports Quarterly Attributable Revenue of $7,301,000 and Adjusted EBITDA of $6,273,000
Marketwired - Wed Mar 16, 7:49AM CDT
Altius Minerals Corporation ("Altius" or the "Corporation" (TSX: ALS) reports attributable revenue (1) of $7,301,000 and adjusted EBITDA (2) of $6,273,000, or $0.16 per share, for the quarter ended January 31, 2016. This compares to attributable revenue of $7,583,000 and adjusted EBITDA of $5,200,000, or $0.16 per share, for the corresponding period last year.
ALS.TO: 9.03 (-0.06)

Evaluating Variations in Equity Market Trading -- Complementary Research on Medical Marijuana, Northstar Electronics, Detour Gold and Altius Minerals
ACCESSWIRE - Wed Mar 16, 7:11AM CDT
NEW YORK, NY / ACCESSWIRE / March 16, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Medical Marijuana Inc. (OTC: MJNA), Northstar Electronics Inc. (OTC: NEIK), Detour Gold Corp (OTC: DRGDF) and Altius Minerals Corp (OTC: ATUSF). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.

Altius Provides Update on 2016 Exploration Initiatives
Marketwired - Mon Mar 14, 7:02AM CDT
Altius Minerals Corporation ("Altius" (TSX: ALS) is pleased to provide an update on its global exploration project generation activities. Over the past year, Altius has strategically increased its portfolio of exploration stage projects within select jurisdictions that are high-ranking both in terms of mineral discovery potential and investment attractiveness. Several consecutive years of deferred exploration investment throughout the minerals sector has resulted in a counter-cyclical opportunity that is marked by significantly enhanced land access and lower generative costs. Our recent efforts have primarily concentrated around opportunities in zinc, copper, gold, nickel and platinum group metals.
ALS.TO: 9.03 (-0.06)

Altius Minerals Has Returned 36.0% Since SmarTrend Recommendation (ATUSF)
Comtex SmarTrend(R) - Wed Feb 03, 10:39AM CST
SmarTrend identified a Downtrend for Altius Minerals (NASDAQ:ATUSF) on November 6th, 2015 at $9.05. In approximately 3 months, Altius Minerals has returned 36.02% as of today's recent price of $5.79.

Altius Minerals Down 36.0% Since SmarTrend Downtrend Call (ATUSF)
Comtex SmarTrend(R) - Wed Feb 03, 10:12AM CST
SmarTrend identified a Downtrend for Altius Minerals (NASDAQ:ATUSF) on November 6th, 2015 at $9.05. In approximately 3 months, Altius Minerals has returned 36.02% as of today's recent price of $5.79.

This Market Is Predictable -- Consensus Reports on Unicharm, Cielo, DREAM Unlimited, and Altius Minerals
ACCESSWIRE - Mon Jan 25, 7:05AM CST
NEW YORK, NY / ACCESSWIRE / January 25, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Unicharm Corp. (OTC: UNICY), Cielo SA (OTC: CIOXY), DREAM Unlimited Corp. (OTC: DRUNF) and Altius Minerals Corp. (OTC: ATUSF). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.

Downtrend Call Working As Altius Minerals Stock Falls 40.0% (ATUSF)
Comtex SmarTrend(R) - Tue Jan 19, 4:58PM CST
SmarTrend identified a Downtrend for Altius Minerals (NASDAQ:ATUSF) on November 6th, 2015 at $9.05. In approximately 2 months, Altius Minerals has returned 39.99% as of today's recent price of $5.43.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 307

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 211

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 246

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 694

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 63

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 351

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 239

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 105

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 27

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 180

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading

Top 5 Most Recently Viewed Articles

b1BANK Partners with Spiral to Enhance Community Banking Impact

Updated Category News Views 97

Enhanced Financial Wellness through Partnership NEW YORK--Today, Spiral, a personalized banking platform, announced a significant partnership with b1BANK, established as a community-focused banking institution. Through this collaboration, the two organizations aim to enhance financial wellness for customers, leveraging b1BANK's dedication to innovative banking solutions...

Continue Reading
AM Best Explores Trends Influencing For-Hire Trucking Industry

Updated Category News Views 168

Insights from AM Best's Latest Webinar on Trucking Trends Viewers can now delve into the highlights from the enlightening webinar hosted by AM Best, titled "For-Hire Trucking: The Risky Road Ahead." This event focused on the intricacies and challenges within the transportation-for-hire trucking sector, providing expert insights into risk management strategies and the...

Continue Reading
BitMart's Creative Campaign to Ignite Offline Crypto Engagement

Updated Category News Views 135

Introducing the Fox Hunt Delivery Campaign BitMart, a leading global cryptocurrency exchange, is excited to announce the launch of the Fox Hunt Delivery Campaign, a unique initiative aimed at boosting cryptocurrency adoption through engaging offline activities. This campaign offers an exciting chance for participants to earn USDT rewards simply by introducing new users to...

Continue Reading
Trinity Capital Inc. Fuels Alt Platform's Growth with $40M Credit

Updated Category News Views 273

Trinity Capital Inc. Supports Alt with Significant Credit Facility Trinity Capital Inc. (NASDAQ: TRIN), a prominent alternative asset manager, is thrilled to announce a groundbreaking agreement with Alt, providing up to $40 million through an asset-based revolving credit facility. This funding aims to bolster Alt's innovative marketplace tailored for trading card...

Continue Reading
Everest Medicines Achieves Record Revenue and Growth in 2024

Updated Category News Views 506

Everest Medicines Achieves Remarkable Financial Success Everest Medicines, a groundbreaking biopharmaceutical company focused on innovative healthcare solutions, has reported remarkable financial results for the year ending December 31, 2024. With a robust revenue growth of 461%, the company stands out in the pharmaceutical industry, showcasing its resilience and dynamic...

Continue Reading